

## DAFTAR PUSTAKA

### Buku

- Atkinson, P. A. (1997). Analysing documentary realities. In D. Silverman, *Qualitative research: Theory, method and practice*, (pp. 45-62). London: Sage Publications.
- Babbie. (1989). *The practice of social research*. Belmont: Wadsworth.
- Blumberg, B. C. (2005). *Business Research Methods*. Maidenhead: McGraw-Hil.
- Brown, T. A. (2006). *Confirmatory factor analysis for applied research*. New York: Guilford.
- Creswell. (2007). *Qualitative inquiry & research design: Choosing among five approaches*. Thousand Oaks: Sage Publications, Inc.
- Hammersley M, A. P. (1995). *Ethnography: principles in practice*. 2nd ed. London: Routledge.
- Henderson, C. W. (2010). *Understanding International Law*. Chichester, West Sussex: John Wiley & Sons Ltd.
- Hiller, T. (1998). *Sourcebook on Public International Law*. London: Cavendish Publishing Limited.
- Intellectual property and access to medicines. (2012). In *Management Sciences for Health*.
- Kruger. (1988). *An introduction to phenomenological psychology*. Cape Town: Juta and Co, Ltd.
- Kvale. (1996). *Interviews*. Thousand Oaks: Sage Publications.
- Lincoln. (1985). *Naturalist inquiry*. Newbury Park,: Sage Publications, Inc.
- Mark Saunders, P. L. (2007). *Research Methods for Business Students*. 4th Edition. Essex: Pearson Education Limited.
- Melfianora. (2019). PENULISAN KARYA TULIS ILMIAH DENGAN STUDI LITERATUR. *UPT Balai Pelatihan Penyuluh Pertanian*, 2-3.
- Merriam, S. B. (1988). *Case study research in education: A qualitative approach*. San Fransisco: Jossey Bass.

- Morse. (1991). *Qualitative nursing research*. Newbury Park: Sage Publications.
- Office, U. I. (2017). *Intellectual property rights in India*. New Port: Crown.
- Patton, M. Q. (2002). *Qualitative research and evaluation methods 3rd ed.* Thousand Oaks: Sage Publications, Inc.
- Pope C, M. N. (1999). *Qualitative Research in Healthcare*. London: BMJ Books.
- Selyawati, N. P. (2020). *Penyelesaian Sengketa (Dispute Settlement) atas Pelanggaran Hak Kekayaan Intelektual Melalui Arbitrase*. Semarang: Universitas Negeri Semarang.
- Silverman. (2000). *Doing qualitative research*. London: Sage Publications.
- Strauss, A. &. (1998). *Basics of qualitative research: Techniques and procedures for developing grounded theory (2nd ed.)*. London: Sage Publications.
- Sugiyono. (2007). *Metode Penelitian Kuantitatif Kualitatif dan R & D*. Bandung: Efabeta.

## **Jurnal**

- AGREEMENT ON TRADE-RELATED ASPECTS OF INTELLECTUAL PROPERTY RIGHTS. (n.d.).
- Arun Kumar, A. N. (2017). Ever-greening in Pharmaceuticals: Strategies, Consequences and Provisions for Prevention in USA, EU, India and Other Countries. *Pharmaceutical Regulatory Affairs Volume 6*, 1.
- Audiya, A. A. (2018). JENIS – JENIS PATEN DAN JANGKA WAKTU PERLINDUNGAN PATEN. *Section Class Content*, 19.
- Beck. (2003). Initiation into qualitative data analysis. *Journal of Nursing Education*, 231.
- Bhaven N. Sampat, K. C. (2018). Indian pharmaceutical patent prosecution: The changing role of Section 3(d). *Journal Pone*, 1-19.
- Bowen, G. A. (2009). Document Analysis as a Qualitative Research Method. *Qualitative Research Journal*, vol. 9, no. 2, 27-40.
- Catbagan, A. (2020). Rights of Action for Private Non-State Actors in the WTO Disputes. *Denver Journal of International Law & Policy*, 279-302.

- Catherine Colston, J. G. (2005). In J. G. Catherine Colston, *Modern Intellectual Property Law* (pp. 163-164).
- Chandra Nath Saha, S. B. (2011). Intellectual property rights: An overview and implications in pharmaceutical industry. *Journal of Advanced Pharmaceutical Technology & Research | Apr-Jun 2011 | Vol 2 | Issue 2*, 88-93.
- Connell, J. L. (2001). Constraints, compromises and choice: Comparing three qualitative research studies. *The Qualitative Report*.
- Ecks, S. (2008). Global pharmaceutical markets and corporate citizenship: The case of Novartis' anti-cancer drug Glivec. *BioSocieties 3* , 165-181.
- Eduardo Urias, S. V. (2020). Access to medicines after TRIPS: Is compulsory licensing an effective mechanism to lower drug prices? A review of the existing evidence. *Journal of International Business Policy*, 367–384.
- Fereday, J. &-C. (2006). Demonstrating rigor using thematic analysis: A hybrid approach of inductive and deductive coding and theme development. *International Journal of Qualitative Methods*, 5(1), 80–92., 80-92.
- Gabriela, S. M. (2013). THE ROLE OF INTERNATIONAL ORGANIZATIONS IN THE GLOBAL ECONOMIC GOVERNANCE – AN ASSESSMENT. *Romanian Economic and Business Review*.
- Gerard Marshall Raj, R. P. (2015). Drug patents and intellectual property rights. *European Journal of Clinical Pharmacology*.
- Ginarte, J. a. (1997). Determinants of Patent Rights: A Cross-national Study. *Research Policy 26*, 283-301.
- Gray, D. E. (2004). *Doing research in the real world*. London: Sage Publications.
- Gurgula, O. (2020). Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene? *IIC (2020) 51:1062–1085*, 1062-1085.
- Hemphill, C. S. (2011). Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals. *Journal of Health Economics 31* (2), 327–39.
- Heseltine, P. (2013). Supreme Court of India rejects Novartis' cancer drug patent. *Future*

- Hetvi Trivedi, V. S. (2017). HUMAN RIGHTS VIS-A-VIS PATENT PROTECTION: A CASE STUDY OF NOVARTIS AG V. UNION OF INDIA. *Commonwealth Law Review Journal*, 64-79.
- Jan Wouters, P. D. (2009). International Organizations as Law-Makers. *Leuven Centre for Global Governance Studies*.
- Jayaraman, K. (2013). Gleevec loses Indian patent. *Nature biotechnology volume 31 NUMBER 5*, 371.
- Kojo, Y. (2018). Global Issues and Business in International Relations: Intellectual Property Rights and Access to Medicines. *International Relations of the Asia-Pacific Volume 18*, 5-23.
- Liu, J. (2015). Compulsory Licensing and Anti-Evergreening: Interpreting the TRIPS Flexibilities in Sections 84 and 3(d) of the Indian Patents Act. *Harvard International Law Journal*, 207-227.
- Manjul Vaidya, S. G. (2018). Changing Dimensions of Drug Patents of Indian Pharmaceutical Industry . *Journal of Intellectual Property Rights*, 111-118.
- Marron, D. D. (2000). Which Countries Protect Intellectual Property? The Case of Software Piracy. *Economic Inquiry* 38, 159-174.
- Meghwal, M. J. (2018). Novartis Case Impact of Section 3(D) of TRIPS on Incremental Pharmaceutical Invention. 1-5.
- Mills, J. B. (2006). The development of constructivist grounded theory. *International Journal of Qualitative Methods*, 25-35.
- Paul Gill, K. F. (2008). Methods of data collection in qualitative research: Interviews and focus groups. *British dental journal* , 291-295.
- Raju, K. D. (2008). INTERPRETATION OF SECTION 3(D) IN THE INDIAN PATENTS ACT 2005: A CASE STUDY OF NOVARTIS. *Indian Journal of Intellectual Property Law* 7, 7-32.
- Ravinder Gabbie, J. C. (2014). To patent or not to patent? the case of Novartis cancer drug Glivec in India. *Globalization and Health*, 1-6.
- Rights, C. o. (2002). Integrating Intellectual Property Rights and Development Policy. *Commission on Intellectual Property Rights*.

- Ryan Cardwell, P. L. (2012). The Effects of the TRIPS Agreement on International Protection of Intellectual Property. *International Trade Journal Volume 26*, 7.
- Ryan Cardwell, P. L. (n.d.). The Effects of the TRIPS Agreement on International Protection of Intellectual Property Rights. *International Trade Journal*.
- Sarika Zambada, B. L. (2014). To Study The Scope & Importance Of Amended Patent Act On Indian Pharmaceutical Company With Respect To Innovation. *Procedia Economics and Finance* , 819-828.
- Sellin, J. A. (2015). Does One Size Fit All? Patents, the Right to Health. *Springer*.
- Sellin, J. A. (2015). Does One Size Fit All? Patents, the Right to Health and Access to Medicines. *Neth Int Law Rev (2015) 62:445–473*, 445-473.
- Shadlen, B. N. (2015). Drug patenting in India: looking back and looking forward. *Nature Reviews: Drug Discovery*, 519-520.
- Shadlen, B. N. (2015). TRIPS implementation and secondary pharmaceutical patenting in Brazil and India. *Studies in Comparative International Development*,, 228-257.
- Shadlen, K. A. (2005). The Political Economy of Intellectual Property Protection: The Case of Software. *International Studies Quarterly 49*, 45-71.
- Shadlen, K. C. (2011). The Political Contradictions of Incremental Innovation: Lessons from Pharmaceutical Patent Examination in Brazil. *Politics & Society 39 (2)*, 143-74.
- Shakouri, N. (2014). Qualitative Research: Incredulity toward Metanarrativeness. *Journal of Education and Human Development, Vol 3, No.2*, 671-680.
- Shalini Arora, R. C. (2016). Section 3(d): Implications and Key Concerns for Pharmaceutical Sector . *Journal of Intellectual Property Rights*, 16-26.
- Shamnad Basheer, P. R. (2013). "DUCKING" TRIPS IN INDIA: A SAGA INVOLVING NOVARTIS AND THE LEGALITY OF SECTION 3(D). *National Law School of India Review*, 78-102.
- Sheehe, J. (2009). Indian Patent Law Walking the Line. *Northwestern Journal of Law and Business*, 577-599.

- Sifle, B. D. (2012). Method decisions: The advantages and disadvantages of quantitative and quantitative modes of inquiry. *Pastrol Psychology*, 61, 721-734.
- Subramaniam, D. (2009). RESURRECTING ROSCOE POUND IN SECTION 3(D): THE GLIVEC GOVERNANCE. *Indian J. Intell. Prop. L.*, 41-50.
- Suwardi, S. S. (2006). Perjanjian Internasional yang dibuat oleh Organisasi Internasional. *Indonesian Journal of Internasional Law*, 494-495.
- Syaputri, Y. (2018). KEPENTINGAN INDIA MENOLAK PERMOHONAN HAK PATEN OBAT KANKER DARI PERUSAHAAN NOVARTIS NEGARA SWISS. *JOM FISIP Vol. 5: Edisi I Januari –Juni 2018*, 2-12.
- Tarsa, K. (2016). Novartis AG v. Union of India: Why the Court’s Narrow Interpretation of Enhanced Efficacy Threatens Domestic and Foreign Drug Development. *Boston College International and Comparative Law Review*, 39-52.
- Turner. (2013). Advantages and disadvantages of quantitative and qualitative research.
- Utomo, T. S. (2008). Eksistensi The TRIPS Safeguards didalam Perjanjian TRIPS: Dalam Perspektif Kesehatan Masyarakat. *MIMBAR HUKUM Volume 20, Nomor 2*, 193-410.
- Vawda, Y. A. (2014). After the Novartis judgment - ‘Evergreening’ will never be the same again! *LAW DEMOCRACY & DEVELOPMENT Volume 18*, 305-316.
- Vickie A. Lambert, C. E. (2012). Qualitative Descriptive Research: An Acceptable Design. *Pacific Rim International Journal of Nursing Research*, 255-256.
- Vitaliy M. Pashkov, I. A. (2016). The impact of the legal regime of intellectual property protection in the pharmaceutical market. *Wiadomości Lekarskie 2016, tom LXIX, nr 3 (cz. II)*, 587-591.

### **Internet**

- Ajayi, V. O. (2017). Primary Sources of Data and Secondary Sources of Data. 2-5.
- Asia, W. H.-E. (2017). *World Health Organization*. Retrieved April 20, 2021, from World Health Organization Web Site: <https://apps.who.int/iris/handle/10665/258915>

- Astrea Legal Associates LLP. (2017, June 26). *Astrea Legal Associates LLP*. Retrieved April 20, 2021, from Astrea Legal Associates LLP Website: <http://www.astrealegal.com>
- Basheer, S. (2009, July 3). *Spicy IP*. Retrieved from Spicy IP Web site: <https://spicyip.com/2009/07/breaking-news-novartis-loses-glivec.html>
- Bria, F. (2014). *Digital Social Innovation Interim report*. European Union.
- Business & Human Rights Resource Centre*. (n.d.). Retrieved April 5, 2021, from Business & Human Rights Resource Centre: <https://www.business-humanrights.org/en/latest-news/novartis-lawsuit-re-india-patent-law-access-to-medicine/>
- Caterin m. Simamora, M. (2017, December 04). *PUSAT PENDIDIKAN DAN PELATIHAN PERDAGANGAN KEMENTERIAN PERDAGANGAN*. Retrieved April 17, 2020, from PUSAT PENELITIAN DAN PELATIHAN PERDAGANGAN KEMENTERIAN PERDAGANGAN: <http://pusdiklat.kemendag.go.id/v2019/article/world-trade-organization-wto>
- Chatterjee, P. (2013, April 1). *Intellectual Property Watch*. Retrieved from Intellectual Property Watch Web site: <https://www.ip-watch.org/2013/04/01/novartis-loses-patent-bid-lessons-from-indias-3d-experience/>
- CESCR. (2000). *Protection of Intellectual Property under the TRIPS Agreement*. Secretariat of the WTO.
- Deshmukh, D. (2004, December 23). Retrieved from <https://indiankanoon.org/>
- Garg, J. B. (2007, December 13). *Mondaq*. Retrieved from Mondaq Web site: <https://www.mondaq.com/india/patent/54494/patent-law-in-india?type=popular>
- Glory, B. (2020, May 04). *Binus University Faculty of Humanities International Relations*. Retrieved from Binus University Faculty of Humanities International Relations Web site: <https://ir.binus.ac.id/2020/05/04/youtube-tujuan-penelitian-eksploratif-deskriptif-eksplanatif-dan-evaluatif/>
- Goundar, S. (2019, May 11). Retrieved from ResearchGate: <https://www.researchgate.net/publication/333015026>

- Grover, A. (2013, June 13). *PEAH - Policies for Equitable Access to Health*. Retrieved April 19, 2021, from PEAH - Policies for Equitable Access to Health Web Site: <http://www.peah.it/2013/06/indian-patent-law-trips-compliant-novartis-judgment-shows-the-way/>
- Hermann, R. M. (2012, 03 02). *Intellectual Property Watch*. Retrieved from Intellectual Property Watch Web site: <http://www.ip-watch.org>
- Hill, A. (2014, May 19). *Pharma File*. Retrieved from Pharma File Web site: <http://www.pharmafile.com/news/186407/novartis-agrees-gleevec-patent-deal>
- Ianev, M. (2018, February 21). Novartis in India: Innovation versus Affordability. *Retake exam assignment, International Business Strategy, 2017-2018*, pp. 1-25.
- Krishnan, V. (2013, April 3). Glivec Patent Denial May Affect Investments to India.
- Lakshmi, R. (2013, April 1). *Washington Post* . Retrieved from Washington Post Web site: [https://www.washingtonpost.com/world/asia\\_pacific/india-rejects-novartis-drug-patent/2013/04/01/bf5f13de-9ab6-11e2-9219-51eb8387e8f1\\_story.html](https://www.washingtonpost.com/world/asia_pacific/india-rejects-novartis-drug-patent/2013/04/01/bf5f13de-9ab6-11e2-9219-51eb8387e8f1_story.html)
- Legal Service India*. (2018, March 1). Retrieved from Legal Service India Web site: <http://www.legalservicesindia.com/law/article/5/7/Product-Patent-and-Exclusive-Marketing-Rights#:~:text=The%20term%20Exclusive%20Marketing%20Rights,pate nt%20application%20in%20the%20country.&text=It%20is%20only%20a %20temporary,a>
- Löfgren, H. (2013, April 4). India's Novartis patent ruling puts health before profits.
- Looney, W. (2013, May 1). *PharmExec*. Retrieved from PharmExec Web site: <https://www.pharmexec.com/view/patent-black-label>
- Looney, W. (2014, April 3). *PharmExec*. Retrieved from PharmExec Web site: <https://www.pharmexec.com/view/patent-black-label-six-side-effects-indias-novartis-glivec-ruling>
- LOW, D. (2013, April 1). Novartis Loses the Glivec Patent Fight in India.
- NDTV*. (2013, April 1). Retrieved from NDTV Web site: <https://www.ndtv.com/business/novartis-loses-landmark-india-patent-case-on-glivec-320291>



- Novartis India*. (2022, May 11). Retrieved from Novartis India: <https://www.novartis.in/about-us/company-history>
- PARMAR, D. (2022, January 17). *AsiaIP Informed Analysis*. Retrieved from AsiaIP Informed Analysis Web site: <https://www.asiaiplaw.com/section/ip-analysts/deferred-examination-patent-strategy-or-business-necessity>
- S. S. RANA & CO. (2022, May 13). Retrieved from S. S. RANA & CO. Web site: <https://ssrana.in/ip-laws/patents/patent-registration-india/#:~:text=India%20follows%20deferred%20examination%20system,rquest%20with%20the%20Patent%20Office.>
- Shakti, M. R. (2022, May 15). *Beml India*. Retrieved from Beml India Web site: [https://www.bemlindia.in/eprocurement/demo\\_doc/IPR\\_Training.pdf](https://www.bemlindia.in/eprocurement/demo_doc/IPR_Training.pdf)
- Staton, T. (2013, April 1). *Fierce Pharma*. Retrieved from Fierce Pharma Web Site: <https://www.fiercepharma.com/pharma/as-novartis-loses-glivec-bid-india-s-war-on-pharma-patents-threatens-to-spread>
- Stoker, L. (2012, September 11). *Pharmaceutical Technology*. Retrieved from Pharmaceutical Technology Web site: <https://www.pharmaceutical-technology.com/uncategorised/newsindian-supreme-court-begins-final-hearing-on-glivec-patent-case/>
- TIMES, T. N. (2013, April 1). The Novartis Patent Case: The Full Supreme Court Ruling.
- Vaish, V. (2017, December 11). *Mondaq*. Retrieved from Mondaq Web site: <https://www.mondaq.com/india/court-procedure/654324/alternate-dispute-resolution-adr-in-india>
- Zinar Omar, F. A. (2020). "Patent vs Patients": A case on Novartis patent application in India. *Corporate Brand Management and Reputation: Master's Cases*, 2-8.